Drug Interaction Report

Mitapivat and Dabrafenib: Interaction Details

A pharmacist-reviewed analysis of the Mitapivat and Dabrafenib interaction: the documented clinical effects, severity rating, onset, mechanism, and management considerations, with cited references throughout.

AI-assisted, pharmacist-reviewed · Source data updated Aug 8, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature

Dabrafenib

Tafinlar
+

Mitapivat

Aqvesme Pyrukynd Pyrukynd®
Dr. Brian Staiger, PharmD, BCPS
Medically reviewed by
Dr. Brian Staiger, PharmD, BCPS
Updated Aug 8, 2026
Editorial policy · Data sources
LinkedIn
Interaction severity
Major
Potentially serious — often needs a change or close monitoring.
How we grade severity & evidence

Severity levels

  • Contraindicated: These should generally not be used together.
  • Major: Potentially serious — often needs a change or close monitoring.
  • Moderate: Can be significant — usually manageable with monitoring.
  • Minor: Usually limited clinical impact.

Evidence grades

  • Established: Well documented — supported by controlled studies or strong clinical data.
  • Probable: Good supporting evidence, though not definitively proven.
  • Suspected: Some evidence suggests this interaction, but it is not well established.
  • Possible: Limited or conflicting evidence; the interaction may occur.
  • Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.

Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.

Of 295 documented Mitapivat interactions, 262 are rated major — including this one.
Worried about symptoms right now? Contact your pharmacist or prescriber, or call Poison Control at 1-800-222-1222 (US). Call 911 for an emergency.
Onset
unspecified
Evidence
theoretical
Severity
Major

What happens

Altered (increased/reduced) mitapivat exposure

Interaction Deep Dive

Avoid coadministration of mitapivat and dabrafenib (moderate CYP3A4 inhibitor) as it may increase mitapivat exposure1. If coadministration is required, do not titrate beyond 20 mg twice daily, and monitor Hb and for adverse reactions 2. Concurrent administration of dabrafenib (CYP3A4 inducer) mitapivat (sensitive CYP3A4 substrate) may reduce the exposure of mitapivat and may result in loss of efficacy of mitapivat. Substitute mitapivat or monitor patients for loss of efficacy of mitapivat if unavoidable 3.

Why it happens (mechanism)

Inhibition of CYP3A4-mediated metabolism of mitapivat; induction of CYP3A4-substrate metabolism of mitapivat

Literature reports

1 report — tap to read

a) In drug interaction studies, coadministration of dabrafenib 150 mg twice daily for 15 days and a single dose of midazolam (a CYP3A4 substrate), decreased midazolam AUC by 65% 3.

Common questions

Can I take Mitapivat and Dabrafenib together?

Altered (increased/reduced) mitapivat exposure Always confirm with your pharmacist or prescriber before making any change.

How serious is the Mitapivat and Dabrafenib interaction?

It is rated major. Potentially serious — often needs a change or close monitoring.

How quickly could this interaction happen?

The documented onset is "unspecified". The timing of this interaction is not well characterized.

How strong is the evidence for this interaction?

The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.

Questions for your pharmacist

  • Does my dose of Mitapivat or Dabrafenib need adjusting while I take them together?
  • What symptoms should prompt me to call you or my prescriber right away?
  • Does the timing of my doses matter for this combination?
  • Is there a safer alternative to one of these medications for me?

References (3)

  1. Product Information: AQVESME™ oral tablets, mitapivat oral tablets. Agios Pharmaceuticals Inc (per FDA), Cambridge, MA, 2025. DailyMed
  2. Product Information: PYRUKYND(R) oral tablets, mitapivat oral tablets. Agios Pharmaceuticals Inc (per FDA), Cambridge, MA, 2025. DailyMed
  3. Product Information: TAFINLAR(R) oral capsules, tablets for suspension, dabrafenib oral capsules, tablets for suspension. Novartis Pharmaceuticals Corporation (per FDA), East Hanover, NJ, 2023. DailyMed
Was this write-up helpful?
Dabrafenib

Keep reading about Dabrafenib

All Dabrafenib interactions (133)
Also serious with: Ketoconazole Topical Oxaliplatin Injection Estradiol Amitriptyline
Mitapivat

Keep reading about Mitapivat

All Mitapivat interactions (295) Mitapivat drug information
Also serious with: Mavacamten Ranolazine Ensitrelvir Zoliflodacin
Beyond drug–drug

These medications also interact with supplements

Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:

Dabrafenib + Activated Charcoal Grapefruit St. John's Wort Acacia Rigidula Adrafinil African Wild Potato Alkanna Alpine Ragwort + 146 more
Mitapivat + Activated Charcoal Grapefruit St. John's Wort Acacia Rigidula Adrafinil African Wild Potato Alkanna Alpine Ragwort + 146 more

major · moderate · minor — check everything you take with our drug–supplement interaction checker.

Check another combination

Our instant two-drug interaction checker is almost here.

Coming soon

The instant two-drug checker is on its way.

In the meantime, browse the directory below to look up any drug and see its documented interactions.

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist
This information is for education, not a substitute for professional medical advice. Do not start, stop, or change any medication without talking to your pharmacist or prescriber.